Medical Devices; Exemptions From Premarket Notification: Class II Devices, 44186-44188 [2020-15256]
Download as PDF
44186
Federal Register / Vol. 85, No. 141 / Wednesday, July 22, 2020 / Rules and Regulations
jbell on DSKBBXCHB2PROD with RULES
supporting the movement of cargo
between the United States and Canada);
• Individuals engaged in official
government travel or diplomatic travel;
• Members of the U.S. Armed Forces,
and the spouses and children of
members of the U.S. Armed Forces,
returning to the United States; and
• Individuals engaged in militaryrelated travel or operations.
The following travel does not fall
within the definition of ‘‘essential
travel’’ for purposes of this
Notification—
• Individuals traveling for tourism
purposes (e.g., sightseeing, recreation,
gambling, or attending cultural events).
At this time, this Notification does not
apply to air, freight rail, or sea travel
between the United States and Canada,
but does apply to passenger rail,
passenger ferry travel, and pleasure boat
travel between the United States and
Canada. These restrictions are
temporary in nature and shall remain in
effect until 11:59 p.m. EDT on August
20, 2020. This Notification may be
amended or rescinded prior to that time,
based on circumstances associated with
the specific threat.
The Commissioner of U.S. Customs
and Border Protection (CBP) is hereby
directed to prepare and distribute
appropriate guidance to CBP personnel
on the continued implementation of the
temporary measures set forth in this
Notification. The CBP Commissioner
may determine that other forms of
travel, such as travel in furtherance of
economic stability or social order,
constitute ‘‘essential travel’’ under this
Notification. Further, the CBP
Commissioner may, on an
individualized basis and for
humanitarian reasons or for other
purposes in the national interest, permit
the processing of travelers to the United
States not engaged in ‘‘essential travel.’’
The Acting Secretary of Homeland
Security, Chad F. Wolf, having reviewed
and approved this document, is
delegating the authority to electronically
sign this document to Chad R. Mizelle,
who is the Senior Official Performing
the Duties of the General Counsel for
DHS, for purposes of publication in the
Federal Register.
Chad R. Mizelle,
Senior Official Performing the Duties of the
General Counsel, U.S. Department of
Homeland Security.
[FR Doc. 2020–15955 Filed 7–21–20; 8:45 am]
BILLING CODE 9112–FP–P
VerDate Sep<11>2014
16:35 Jul 21, 2020
Jkt 250001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 884, 888, and 890
[Docket No. FDA–2019–N–2686]
Medical Devices; Exemptions From
Premarket Notification: Class II
Devices
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Final amendment; final order.
The Food and Drug
Administration (FDA or the Agency) is
publishing an order setting forth the
Agency’s final determination to exempt
a list of class II devices from premarket
notification (510(k)) requirements,
subject to certain limitations. This
exemption from 510(k), subject to
certain limitations, is immediately in
effect for the list of class II devices. The
exemption will decrease regulatory
burdens on the medical device industry
and will eliminate private costs and
expenditures required to comply with
certain Federal regulations. FDA is also
amending the codified language for the
list of class II devices to reflect this final
determination. FDA is publishing this
order in accordance with the Federal
Food, Drug, and Cosmetic Act (FD&C
Act).
SUMMARY:
DATES:
This order is effective July 22,
2020.
FOR FURTHER INFORMATION CONTACT:
Jismi Johnson, Center for Devices and
Radiological Health, Food and Drug
Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1528, Silver Spring,
MD 20993, 301–796–6424,
Jismi.johnson@fda.hhs.gov.
SUPPLEMENTARY INFORMATION:
I. Background
Under section 510(k) of the FD&C Act
(21 U.S.C. 360(k)) and its implementing
regulations in part 807, subpart E (21
CFR part 807, subpart E), persons who
propose to begin the introduction or
delivery for introduction into interstate
commerce for commercial distribution
of a device intended for human use are
required to submit a 510(k) to FDA. The
device may not be marketed until FDA
finds it ‘‘substantially equivalent’’
within the meaning of section 513(i) of
the FD&C Act (21 U.S.C. 360c(i)) to a
legally marketed device that does not
require premarket approval.
On December 13, 2016, the 21st
Century Cures Act (Cures Act) (Pub. L.
114–255) was signed into law. Section
3054 of the Cures Act amended section
PO 00000
Frm 00042
Fmt 4700
Sfmt 4700
510(m) of the FD&C Act. As amended,
section 510(m)(2) of the FD&C Act
provides that, 1 calendar day after the
date of publication of the final list under
section 510(m)(1)(B) of the FD&C Act,1
FDA may exempt a class II device from
the requirement to submit a report
under section 510(k) of the FD&C Act,
upon its own initiative or a petition of
an interested person, if FDA determines
that a 510(k) is not necessary to provide
reasonable assurance of the safety and
effectiveness of the device. This section
requires FDA to publish in the Federal
Register a notice of intent to exempt a
device, or of the petition, and provide
a 60-calendar-day comment period.
Within 120 days of publication of such
notice, FDA shall publish an order in
the Federal Register that sets forth its
final determination regarding the
exemption of the device that was the
subject of the notice.
In the Federal Register of October 25,
2019 (84 FR 57445), in accordance with
the amendments to section 510(m)(2) of
the FD&C Act, on its own initiative,
FDA issued a notice of intent to exempt
the identified class II devices from
premarket notification requirements
under section 510(k) of the FD&C Act,
subject to certain limitations. Having
received no comments to the docket
following a 60-day comment period,
FDA is issuing this order to set forth our
final determination to exempt the class
II devices that were the subject of the
notice. Through this action, FDA is now
amending the codified language for each
identified classification regulation to
reflect our final determinations for these
class II exemptions.2
II. Criteria for Exemption
There are a number of factors FDA
may consider to determine whether a
510(k) is necessary to provide
reasonable assurance of the safety and
effectiveness of a class II device. These
factors are discussed in the January 21,
1998, Federal Register notice (63 FR
3142) and subsequently in the guidance
we issued on February 19, 1998, entitled
‘‘Procedures for Class II Device
Exemptions From Premarket
Notification, Guidance for Industry and
1 FDA published the final list under section
510(m)(1)(B) of the FD&C Act in the Federal
Register of July 11, 2017 (82 FR 31976).
2 FDA notes that the ‘‘ACTION’’ caption for this
final order is styled as ‘‘Final amendment; final
order,’’ rather than ‘‘Final order.’’ Beginning in
December 2019, this editorial change was made to
indicate that the document ‘‘amends’’ the Code of
Federal Regulations. The change was made in
accordance with the Office of Federal Register’s
(OFR) interpretations of the Federal Register Act (44
U.S.C. chapter 15), its implementing regulations (1
CFR 5.9 and parts 21 and 22), and the Document
Drafting Handbook.
E:\FR\FM\22JYR1.SGM
22JYR1
Federal Register / Vol. 85, No. 141 / Wednesday, July 22, 2020 / Rules and Regulations
CDRH Staff’’ (‘‘Class II 510(k)
Exemption Guidance’’). That guidance
can be obtained through the internet at
https://www.fda.gov/downloads/
MedicalDevices/DeviceRegulation
andGuidance/GuidanceDocuments/
UCM080199.pdf or by sending an email
request to CDRH-Guidance@fda.hhs.gov
to receive a copy of the document.
Please use the document number 159 to
identify the guidance you are
requesting.
III. Limitations on Exemptions
FDA has determined that premarket
notification is not necessary to provide
a reasonable assurance of safety and
effectiveness of the class II devices
listed in table 1. This determination is
based, in part, on the Agency’s
knowledge of the device, including past
experience and relevant reports or
studies on device performance (as
appropriate), the applicability of general
and special controls, and the Agency’s
ability to limit an exemption.
A. General Limitations of Exemptions
FDA’s exemption from premarket
notification for the class II devices listed
in table 1 applies only to those devices
that have existing or reasonably
foreseeable characteristics of
commercially distributed devices within
that generic type. A manufacturer of a
listed device would still be required to
submit a premarket notification to FDA
before introducing a device or
delivering it for introduction into
commercial distribution when the
device meets any of the conditions
described in 21 CFR 884.9, 888.9, and
890.9.
B. Partial Limitations of Exemptions
In addition to the general limitations,
FDA may also partially limit an
exemption from premarket notification
requirements to specific devices within
a listed device type when an initial
Agency assessment determines that the
factors laid out in the Class II 510(k)
Exemption Guidance do not weigh in
favor of exemption for all devices in a
particular group. In such situations
where a partial exemption limitation
has been identified, FDA has
determined that premarket notification
is necessary to provide a reasonable
assurance of safety and effectiveness for
these devices. In table 1, for example,
FDA is listing the exemption of the
optical position/movement recording
system but limits the exemption to such
devices that are for prescription use
only. FDA believes that premarket
review (e.g., premarket notification) of
an optical position/movement recording
44187
system for over-the-counter (OTC) use is
necessary to ensure that the exercises
and activities led by the system are
appropriate for a user’s rehabilitation
and to assess the measurement accuracy
of the system. Additionally, a
therapeutic massager to internally
massage trigger points in the pelvic floor
musculature would exceed the
exemption limitation and would require
510(k) review if it is indicated for OTC
use, lacks a quantitative feedback
mechanism, or lacks a disposable
covering.
IV. List of Class II Devices
In this final order, FDA is identifying
the following list of class II devices that
no longer require premarket notification
under section 510(k) of the FD&C Act,
subject to the general limitations to the
exemptions found in 21 CFR 884.9,
888.9, and 890.9 and any partial
exemption limitations identified in
Table 1.
FDA assigned new product codes to
the device types that are exempt subject
to the partial limitations to ensure that
these devices can be separated from
devices that do not fall within the
partial exemption limitation under the
existing product code (i.e., exempt and
non-exempt devices within a device
type now have distinct product codes).
TABLE 1—CLASS II DEVICES
21 CFR section
Device type
Exempt
product code
Non-exempt
product code
(non-exempt)
Partial exemption limitation
(if applicable)
884.6120 .............
Accessory, Assisted Reproduction.
Media, Reproductive .............
QKH ..............
MQG ..............
QKI ................
MQL ..............
Instruments Designed for
Press-Fit Osteochondral
implants.
Interactive Rehabilitation Exercise Devices.
Massager, Therapeutic, to
Internally Massage Trigger
Points in the Pelvic Floor
Musculature.
Not Applicable
QBO ..............
Exemption is limited to assisted reproduction laminar flow
workstations.
Exemption is limited to phosphate-buffered saline used for
washing, and short-term handling and manipulation of
gametes and embryos; culture oil used as an overlay
for culture media containing gametes and embryos; and
water for assisted reproduction applications.
Not Applicable.
QKC ..............
LXJ ................
Exemption is limited to prescription (Rx) use only.
QKD ..............
OSD ..............
Exemption is limited to prescription (Rx) use only devices
which incorporate a quantitative feedback mechanism
and a disposable covering.
884.6180 .............
888.4505 .............
890.5360 * ...........
890.5670 .............
jbell on DSKBBXCHB2PROD with RULES
* FDA is revising the name of the device type under product code LXJ from ‘‘System, Optical Position/Movement Recording’’ to ‘‘Interactive Rehabilitation Exercise Devices.’’
FDA is also revising the name of
product code LXJ to further clarify the
device type that this product code is
intended to represent, identified with an
asterisk in table 1. The device type was
previously ‘‘System, Optical Position/
Movement Recording.’’ This product
code also includes types of
rehabilitation devices other than optical
VerDate Sep<11>2014
16:35 Jul 21, 2020
Jkt 250001
position/movement recording systems;
therefore, to more accurately reflect the
devices which fall within this device
type (product code LXJ), the device type
has been renamed ‘‘Interactive
Rehabilitation Exercise Devices.’’ The
new product code, QKC, which
represents the class II exempt
counterpart of LXJ and reflects the
PO 00000
Frm 00043
Fmt 4700
Sfmt 4700
partial exemption limited to
prescription use, also reflects this name
change.
V. Analysis of Environmental Impact
The Agency has determined under 21
CFR 25.30(h) that this action is of a type
that does not individually or
cumulatively have a significant effect on
the human environment. Therefore,
E:\FR\FM\22JYR1.SGM
22JYR1
44188
Federal Register / Vol. 85, No. 141 / Wednesday, July 22, 2020 / Rules and Regulations
neither an environmental assessment
nor an environmental impact statement
is required.
VI. Paperwork Reduction Act of 1995
FDA concludes that this final order
contains no new collection of
information. Therefore, clearance by the
Office of Management and Budget
(OMB) under the Paperwork Reduction
Act of 1995 (44 U.S.C. 3501–3521) is not
required. This final order refers to
previously approved FDA collections of
information. These collections of
information are subject to review by
OMB under the PRA. The collections of
information in in 21 CFR part 807,
subpart E, regarding premarket
notification submissions, have been
approved under OMB control number
0910–0120; the collections of
information in 21 CFR parts 801 and
809, regarding labeling, have been
approved under OMB control number
0910–0485; and the collections of
information in part 820, regarding
quality system regulation, have been
approved under OMB control number
0910–0073.
List of Subjects in 21 CFR Parts 884,
888, and 890
Medical devices.
Therefore, under the Federal Food,
Drug, and Cosmetic Act and under
authority delegated to the Commissioner
of Food and Drugs, 21 CFR parts 884,
888, and 890 are amended as follows:
PART 884—OBSTETRICAL AND
GYNECOLOGICAL DEVICES
1. The authority citation for part 884
continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 360l, 371.
2. In § 884.6120, revise paragraph (b)
to read as follows:
■
§ 884.6120 Assisted reproduction
accessories.
jbell on DSKBBXCHB2PROD with RULES
*
16:35 Jul 21, 2020
Jkt 250001
*
*
*
*
*
(b) Classification. Class II (special
controls) (mouse embryo assay
information, endotoxin testing,
sterilization validation, design
specifications, labeling requirements,
biocompatibility testing, and clinical
testing). The device, when it is
phosphate-buffered saline used for
washing, and short-term handling and
manipulation of gametes and embryos;
culture oil used as an overlay for culture
media containing gametes and embryos;
and water for assisted reproduction
applications, is exempt from the
premarket notification procedures in
subpart E of part 807 of this chapter
subject to the limitations in § 884.9.
PART 888—ORTHOPEDIC DEVICES
(b) Classification. Class II (special
controls). The device, when it is for
prescription use only with a
quantitative feedback mechanism and a
disposable covering, is exempt from the
premarket notification procedures in
subpart E of part 807 of this chapter
subject to the limitations in § 890.9. The
special controls for this device are:
*
*
*
*
*
Dated: July 9, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020–15256 Filed 7–21–20; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF STATE
22 CFR Part 126
[Public Notice 10969]
4. The authority citation for part 888
continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 360l, 371.
5. Amend § 888.4505 by revising
paragraph (b) introductory text to read
as follows:
■
§ 888.4505 Orthopedic surgical
instrumentation designed for osteochondral
implants with press-fit fixation.
*
*
*
*
*
(b) Classification. Class II (special
controls). The device is exempt from the
premarket notification procedures in
subpart E of part 807 of this chapter
subject to the limitations in § 888.9. The
special controls for this device are:
*
*
*
*
*
PART 890—PHYSICAL MEDICINE
DEVICES
6. The authority citation for part 890
continues to read as follows:
■
Authority: 21 U.S.C. 351, 360, 360c, 360e,
360j, 360l, 371.
7. In § 890.5360, revise paragraph (b)
to read as follows:
■
*
*
*
*
(b) Classification. Class II (special
controls) (design specifications, labeling
requirements, and clinical testing). The
device, when it is a simple embryo
incubator with only temperature, gas,
and humidity control; a syringe pump;
a collection tube warmer; a dish/plate/
microscope stage warmer; a controlledrate cryopreservation freezer; or an
assisted reproduction laminar flow
workstation is exempt from the
premarket notification procedures in
subpart E of part 807 of this chapter
subject to the limitations in § 884.9.
■ 3. In § 884.6180, revise paragraph (b)
to read as follows:
VerDate Sep<11>2014
§ 884.6180 Reproductive media and
supplements.
§ 890.5360
Measuring exercise equipment.
*
*
*
*
*
(b) Classification. Class II (special
controls). The device, when it is a
measuring exerciser or an interactive
rehabilitation exercise device for
prescription use only, is exempt from
the premarket notification procedures in
subpart E of part 807 of this chapter
subject to the limitations in § 890.9.
■ 8. Amend § 890.5670 by revising
paragraph (b) introductory text to read
as follows:
§ 890.5670
Internal therapeutic massager.
*
*
PO 00000
*
Frm 00044
*
Fmt 4700
*
Sfmt 4700
RIN 1400–AE97
International Traffic in Arms
Regulations: Amendment of Central
African Republic
Department of State.
Final rule.
AGENCY:
ACTION:
The Department of State is
amending the International Traffic in
Arms Regulations (ITAR) to reflect
recently adopted United Nations
Security Council Resolutions (UNSCRs)
concerning the Central African
Republic.
SUMMARY:
DATES:
The rule is effective on July 22,
2020.
Ms.
Engda Wubneh, Foreign Affairs Officer,
Office of Defense Trade Controls Policy,
U.S. Department of State, telephone
(202) 663–1809, or email
DDTCResponseTeam@state.gov. ATTN:
Regulatory Change, ITAR Section 126.1
Central African Republic Update 2020.
SUPPLEMENTARY INFORMATION: On
September 12, 2019, the United Nations
Security Council (UNSC) adopted
resolution 2488, which adjusted the
arms embargo on the Central African
Republic (CAR) to allow additional
exceptions to the embargo and
committed to further review of the
sanctions regime within four months.
On January 31, 2020, four months later,
the UNSC adopted resolution 2507
renewing that arms embargo until July
31, 2020 and providing additional
exceptions to those adopted by
resolution 2488. The UNSC initially
imposed an arms embargo on the
country with certain enumerated
exceptions in 2013. The CAR
government has made progress since,
FOR FURTHER INFORMATION CONTACT:
E:\FR\FM\22JYR1.SGM
22JYR1
Agencies
[Federal Register Volume 85, Number 141 (Wednesday, July 22, 2020)]
[Rules and Regulations]
[Pages 44186-44188]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-15256]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
21 CFR Parts 884, 888, and 890
[Docket No. FDA-2019-N-2686]
Medical Devices; Exemptions From Premarket Notification: Class II
Devices
AGENCY: Food and Drug Administration, HHS.
ACTION: Final amendment; final order.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or the Agency) is
publishing an order setting forth the Agency's final determination to
exempt a list of class II devices from premarket notification (510(k))
requirements, subject to certain limitations. This exemption from
510(k), subject to certain limitations, is immediately in effect for
the list of class II devices. The exemption will decrease regulatory
burdens on the medical device industry and will eliminate private costs
and expenditures required to comply with certain Federal regulations.
FDA is also amending the codified language for the list of class II
devices to reflect this final determination. FDA is publishing this
order in accordance with the Federal Food, Drug, and Cosmetic Act (FD&C
Act).
DATES: This order is effective July 22, 2020.
FOR FURTHER INFORMATION CONTACT: Jismi Johnson, Center for Devices and
Radiological Health, Food and Drug Administration, 10903 New Hampshire
Ave., Bldg. 66, Rm. 1528, Silver Spring, MD 20993, 301-796-6424,
[email protected].
SUPPLEMENTARY INFORMATION:
I. Background
Under section 510(k) of the FD&C Act (21 U.S.C. 360(k)) and its
implementing regulations in part 807, subpart E (21 CFR part 807,
subpart E), persons who propose to begin the introduction or delivery
for introduction into interstate commerce for commercial distribution
of a device intended for human use are required to submit a 510(k) to
FDA. The device may not be marketed until FDA finds it ``substantially
equivalent'' within the meaning of section 513(i) of the FD&C Act (21
U.S.C. 360c(i)) to a legally marketed device that does not require
premarket approval.
On December 13, 2016, the 21st Century Cures Act (Cures Act) (Pub.
L. 114-255) was signed into law. Section 3054 of the Cures Act amended
section 510(m) of the FD&C Act. As amended, section 510(m)(2) of the
FD&C Act provides that, 1 calendar day after the date of publication of
the final list under section 510(m)(1)(B) of the FD&C Act,\1\ FDA may
exempt a class II device from the requirement to submit a report under
section 510(k) of the FD&C Act, upon its own initiative or a petition
of an interested person, if FDA determines that a 510(k) is not
necessary to provide reasonable assurance of the safety and
effectiveness of the device. This section requires FDA to publish in
the Federal Register a notice of intent to exempt a device, or of the
petition, and provide a 60-calendar-day comment period. Within 120 days
of publication of such notice, FDA shall publish an order in the
Federal Register that sets forth its final determination regarding the
exemption of the device that was the subject of the notice.
---------------------------------------------------------------------------
\1\ FDA published the final list under section 510(m)(1)(B) of
the FD&C Act in the Federal Register of July 11, 2017 (82 FR 31976).
---------------------------------------------------------------------------
In the Federal Register of October 25, 2019 (84 FR 57445), in
accordance with the amendments to section 510(m)(2) of the FD&C Act, on
its own initiative, FDA issued a notice of intent to exempt the
identified class II devices from premarket notification requirements
under section 510(k) of the FD&C Act, subject to certain limitations.
Having received no comments to the docket following a 60-day comment
period, FDA is issuing this order to set forth our final determination
to exempt the class II devices that were the subject of the notice.
Through this action, FDA is now amending the codified language for each
identified classification regulation to reflect our final
determinations for these class II exemptions.\2\
---------------------------------------------------------------------------
\2\ FDA notes that the ``ACTION'' caption for this final order
is styled as ``Final amendment; final order,'' rather than ``Final
order.'' Beginning in December 2019, this editorial change was made
to indicate that the document ``amends'' the Code of Federal
Regulations. The change was made in accordance with the Office of
Federal Register's (OFR) interpretations of the Federal Register Act
(44 U.S.C. chapter 15), its implementing regulations (1 CFR 5.9 and
parts 21 and 22), and the Document Drafting Handbook.
---------------------------------------------------------------------------
II. Criteria for Exemption
There are a number of factors FDA may consider to determine whether
a 510(k) is necessary to provide reasonable assurance of the safety and
effectiveness of a class II device. These factors are discussed in the
January 21, 1998, Federal Register notice (63 FR 3142) and subsequently
in the guidance we issued on February 19, 1998, entitled ``Procedures
for Class II Device Exemptions From Premarket Notification, Guidance
for Industry and
[[Page 44187]]
CDRH Staff'' (``Class II 510(k) Exemption Guidance''). That guidance
can be obtained through the internet at https://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM080199.pdf or by sending an email request to [email protected] to receive a copy of the document. Please use the
document number 159 to identify the guidance you are requesting.
III. Limitations on Exemptions
FDA has determined that premarket notification is not necessary to
provide a reasonable assurance of safety and effectiveness of the class
II devices listed in table 1. This determination is based, in part, on
the Agency's knowledge of the device, including past experience and
relevant reports or studies on device performance (as appropriate), the
applicability of general and special controls, and the Agency's ability
to limit an exemption.
A. General Limitations of Exemptions
FDA's exemption from premarket notification for the class II
devices listed in table 1 applies only to those devices that have
existing or reasonably foreseeable characteristics of commercially
distributed devices within that generic type. A manufacturer of a
listed device would still be required to submit a premarket
notification to FDA before introducing a device or delivering it for
introduction into commercial distribution when the device meets any of
the conditions described in 21 CFR 884.9, 888.9, and 890.9.
B. Partial Limitations of Exemptions
In addition to the general limitations, FDA may also partially
limit an exemption from premarket notification requirements to specific
devices within a listed device type when an initial Agency assessment
determines that the factors laid out in the Class II 510(k) Exemption
Guidance do not weigh in favor of exemption for all devices in a
particular group. In such situations where a partial exemption
limitation has been identified, FDA has determined that premarket
notification is necessary to provide a reasonable assurance of safety
and effectiveness for these devices. In table 1, for example, FDA is
listing the exemption of the optical position/movement recording system
but limits the exemption to such devices that are for prescription use
only. FDA believes that premarket review (e.g., premarket notification)
of an optical position/movement recording system for over-the-counter
(OTC) use is necessary to ensure that the exercises and activities led
by the system are appropriate for a user's rehabilitation and to assess
the measurement accuracy of the system. Additionally, a therapeutic
massager to internally massage trigger points in the pelvic floor
musculature would exceed the exemption limitation and would require
510(k) review if it is indicated for OTC use, lacks a quantitative
feedback mechanism, or lacks a disposable covering.
IV. List of Class II Devices
In this final order, FDA is identifying the following list of class
II devices that no longer require premarket notification under section
510(k) of the FD&C Act, subject to the general limitations to the
exemptions found in 21 CFR 884.9, 888.9, and 890.9 and any partial
exemption limitations identified in Table 1.
FDA assigned new product codes to the device types that are exempt
subject to the partial limitations to ensure that these devices can be
separated from devices that do not fall within the partial exemption
limitation under the existing product code (i.e., exempt and non-exempt
devices within a device type now have distinct product codes).
Table 1--Class II Devices
----------------------------------------------------------------------------------------------------------------
Non-exempt Partial exemption
21 CFR section Device type Exempt product product code limitation (if
code (non-exempt) applicable)
----------------------------------------------------------------------------------------------------------------
884.6120....................... Accessory, QKH.............. MQG.............. Exemption is limited
Assisted to assisted
Reproduction. reproduction laminar
flow workstations.
884.6180....................... Media, QKI.............. MQL.............. Exemption is limited
Reproductive. to phosphate-buffered
saline used for
washing, and short-
term handling and
manipulation of
gametes and embryos;
culture oil used as
an overlay for
culture media
containing gametes
and embryos; and
water for assisted
reproduction
applications.
888.4505....................... Instruments Not Applicable... QBO.............. Not Applicable.
Designed for
Press-Fit
Osteochondral
implants.
890.5360 *..................... Interactive QKC.............. LXJ.............. Exemption is limited
Rehabilitation to prescription (Rx)
Exercise Devices. use only.
890.5670....................... Massager, QKD.............. OSD.............. Exemption is limited
Therapeutic, to to prescription (Rx)
Internally use only devices
Massage Trigger which incorporate a
Points in the quantitative feedback
Pelvic Floor mechanism and a
Musculature. disposable covering.
----------------------------------------------------------------------------------------------------------------
* FDA is revising the name of the device type under product code LXJ from ``System, Optical Position/Movement
Recording'' to ``Interactive Rehabilitation Exercise Devices.''
FDA is also revising the name of product code LXJ to further
clarify the device type that this product code is intended to
represent, identified with an asterisk in table 1. The device type was
previously ``System, Optical Position/Movement Recording.'' This
product code also includes types of rehabilitation devices other than
optical position/movement recording systems; therefore, to more
accurately reflect the devices which fall within this device type
(product code LXJ), the device type has been renamed ``Interactive
Rehabilitation Exercise Devices.'' The new product code, QKC, which
represents the class II exempt counterpart of LXJ and reflects the
partial exemption limited to prescription use, also reflects this name
change.
V. Analysis of Environmental Impact
The Agency has determined under 21 CFR 25.30(h) that this action is
of a type that does not individually or cumulatively have a significant
effect on the human environment. Therefore,
[[Page 44188]]
neither an environmental assessment nor an environmental impact
statement is required.
VI. Paperwork Reduction Act of 1995
FDA concludes that this final order contains no new collection of
information. Therefore, clearance by the Office of Management and
Budget (OMB) under the Paperwork Reduction Act of 1995 (44 U.S.C. 3501-
3521) is not required. This final order refers to previously approved
FDA collections of information. These collections of information are
subject to review by OMB under the PRA. The collections of information
in in 21 CFR part 807, subpart E, regarding premarket notification
submissions, have been approved under OMB control number 0910-0120; the
collections of information in 21 CFR parts 801 and 809, regarding
labeling, have been approved under OMB control number 0910-0485; and
the collections of information in part 820, regarding quality system
regulation, have been approved under OMB control number 0910-0073.
List of Subjects in 21 CFR Parts 884, 888, and 890
Medical devices.
Therefore, under the Federal Food, Drug, and Cosmetic Act and under
authority delegated to the Commissioner of Food and Drugs, 21 CFR parts
884, 888, and 890 are amended as follows:
PART 884--OBSTETRICAL AND GYNECOLOGICAL DEVICES
0
1. The authority citation for part 884 continues to read as follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 360l, 371.
0
2. In Sec. 884.6120, revise paragraph (b) to read as follows:
Sec. 884.6120 Assisted reproduction accessories.
* * * * *
(b) Classification. Class II (special controls) (design
specifications, labeling requirements, and clinical testing). The
device, when it is a simple embryo incubator with only temperature,
gas, and humidity control; a syringe pump; a collection tube warmer; a
dish/plate/microscope stage warmer; a controlled-rate cryopreservation
freezer; or an assisted reproduction laminar flow workstation is exempt
from the premarket notification procedures in subpart E of part 807 of
this chapter subject to the limitations in Sec. 884.9.
0
3. In Sec. 884.6180, revise paragraph (b) to read as follows:
Sec. 884.6180 Reproductive media and supplements.
* * * * *
(b) Classification. Class II (special controls) (mouse embryo assay
information, endotoxin testing, sterilization validation, design
specifications, labeling requirements, biocompatibility testing, and
clinical testing). The device, when it is phosphate-buffered saline
used for washing, and short-term handling and manipulation of gametes
and embryos; culture oil used as an overlay for culture media
containing gametes and embryos; and water for assisted reproduction
applications, is exempt from the premarket notification procedures in
subpart E of part 807 of this chapter subject to the limitations in
Sec. 884.9.
PART 888--ORTHOPEDIC DEVICES
0
4. The authority citation for part 888 continues to read as follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 360l, 371.
0
5. Amend Sec. 888.4505 by revising paragraph (b) introductory text to
read as follows:
Sec. 888.4505 Orthopedic surgical instrumentation designed for
osteochondral implants with press-fit fixation.
* * * * *
(b) Classification. Class II (special controls). The device is
exempt from the premarket notification procedures in subpart E of part
807 of this chapter subject to the limitations in Sec. 888.9. The
special controls for this device are:
* * * * *
PART 890--PHYSICAL MEDICINE DEVICES
0
6. The authority citation for part 890 continues to read as follows:
Authority: 21 U.S.C. 351, 360, 360c, 360e, 360j, 360l, 371.
0
7. In Sec. 890.5360, revise paragraph (b) to read as follows:
Sec. 890.5360 Measuring exercise equipment.
* * * * *
(b) Classification. Class II (special controls). The device, when
it is a measuring exerciser or an interactive rehabilitation exercise
device for prescription use only, is exempt from the premarket
notification procedures in subpart E of part 807 of this chapter
subject to the limitations in Sec. 890.9.
0
8. Amend Sec. 890.5670 by revising paragraph (b) introductory text to
read as follows:
Sec. 890.5670 Internal therapeutic massager.
* * * * *
(b) Classification. Class II (special controls). The device, when
it is for prescription use only with a quantitative feedback mechanism
and a disposable covering, is exempt from the premarket notification
procedures in subpart E of part 807 of this chapter subject to the
limitations in Sec. 890.9. The special controls for this device are:
* * * * *
Dated: July 9, 2020.
Lowell J. Schiller,
Principal Associate Commissioner for Policy.
[FR Doc. 2020-15256 Filed 7-21-20; 8:45 am]
BILLING CODE 4164-01-P